OverviewChartNewsTraderScreen

HSBC TUR.WAR.OP.END. NOVA/  DE000HS163Z5  /

gettex Zettex2
10/06/2024  21:35:07 Chg.+0.0100 Bid21:59:58 Ask21:59:58 Underlying Strike price Expiration date Option type
1.0700EUR +0.94% 1.0700
Bid Size: 200,000		 1.0800
Ask Size: 200,000		 Novo Nordisk 86.7145 USD 31/12/2078 Call
GlobeNewswire 10/06 RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
GlobeNewswire 10/06 Veru to Present at the American Diabetes Association's 84th Scientific Sessions
GlobeNewswire 03/06 Aeterna Zentaris and Ceapro Complete Merger Transaction
GlobeNewswire 03/06 Aeterna Zentaris and Ceapro Complete Merger Transaction
GlobeNewswire 31/05 Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia...
GlobeNewswire 30/05 Anaqua Annual User Experience Conference to Feature Keynotes from Microsoft, SAP, USPTO, and More
GlobeNewswire 22/05 Veru to Present at the Jefferies Global Healthcare Conference
GlobeNewswire 15/05 Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Cl...
GlobeNewswire 15/05 Aeterna Zentaris Reports First Quarter 2024 Financial Results
GlobeNewswire 14/05 Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Sci...
GlobeNewswire 09/05 US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire 07/05 Vect-Horus to Take Part in a Roundtable Discussion at Viva Technology Conference
TeleTrader 25/04 Europe opens mostly down after corporate earnings
GlobeNewswire 22/04 Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to...
GlobeNewswire 22/04 SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into cli...
GlobeNewswire 22/04 SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into cli...
GlobeNewswire 11/04 Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
GlobeNewswire 02/04 Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...
GlobeNewswire 02/04 Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
GlobeNewswire 28/03 Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategi...
GlobeNewswire 27/03 Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completio...
GlobeNewswire 25/03 Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the ...
GlobeNewswire 18/03 Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ ...
GlobeNewswire 15/03 American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...
GlobeNewswire 15/03 University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated...